Drug Trial Radar · NCT06305767
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Last checked: Nov 20, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
230
Planned (sponsor's estimate)
Start
Mar 28, 2024
Primary completion
Apr 23, 2027
Study completion Oct 20, 2031
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- ModernaTX, Inc.
- First posted
- Mar 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat people with high-risk muscle-invasive urothelial carcinoma (MIUC). Urothelial carcinoma is a type of bladder cancer that begins in cells that line the inside of the bladder and other parts of the urinary tract, such as part of the kidneys, ureters, and urethra. People with MIUC usually have chemotherapy before surgery, then surgery to remove the cancer. Chemotherapy is a type of medicine to destroy cancer cells or stop them from growing. After surgery, some people receive more treatment to prevent cancer from returning. Pembrolizumab is an immunotherapy, which is a treatment that helps the immune system fight cancer. Enfortumab vedotin (EV) is an antibody drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. Researchers want to learn if giving intismeran autogene (the study treatment) with pembrolizumab can prevent MIUC from returning after surgery. Intismeran autogene (also called mRNA-4157) is designed to treat each person's cancer by helping the person's immune system identify and kill cancer cells based on certain proteins found on those cancer cells. The goals of this study are to learn if people who receive intismeran autogene and pembrolizumab are alive and cancer free longer than those who receive placebo and pembrolizumab, and to learn about the safety of intismeran autogene, pembrolizumab, and EV, and if people tolerate them.
Conditions
- Bladder Cancer
Interventions
PembrolizumabBiological
Administered via intravenous (IV) infusion at a dose of 400 mg on Day 1 of every 6-week cycle for up to 9 adjuvant cycles for Adjuvant Cohort participants, or at a dose of 200 mg on Day 1 of every cycle for up to four 3-week neoadjuvant cycles and up to thirteen 3-week adjuvant cycles for Perioperative Cohort participants.
Intismeran autogeneBiological
Administered via intramuscular (IM) injection at a dose of 1 mg every 3 weeks for a total of up to 9 adjuvant doses for Adjuvant Cohort participants, or at a dose of 1 mg every 3 weeks for a total of up to 9 doses in the neoadjuvant and adjuvant periods for Perioperative Cohort participants.
PlaceboOther
Intismeran autogene diluent only (saline and/or dextrose) administered via IM injection Q3W for up to 9 doses.
Enfortumab VedotinBiological
Administered via IV infusion at a dose of 1.25 mg/kg on Day 1 and Day 8 of every cycle for up to four 3-week neoadjuvant cycles and up to five 3-week adjuvant cycles for Perioperative Cohort participants.
Surgery (RC plus PLND)Procedure
Curative intent surgery (RC plus PLND) will be administered to all participants in the Perioperative Cohort and will be done in accordance with the American Urological Association/American Society for Radiation Oncology/American Society of Clinical Oncology/Society of Urologic Oncology guidelines. RC plus PLND will be performed within 6 weeks of the last dose of neoadjuvant intismeran autogene plus pembrolizumab plus EV treatment. Adjuvant intismeran autogene plus pembrolizumab plus EV treatment will begin within 8 weeks of completing RC plus PLND.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adjuvant Cohort: Disease Free Survival (DFS)Time frame: Up to approximately 28 months
- Perioperative Cohort: Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 19 months
- Perioperative Cohort: Number of Participants Who Discontinue Study Treatment Due to AETime frame: Up to approximately 16 months
Locations
74 sites in 16 countries. Site status is shown where the registry gives one.
UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 0104)
Los Angeles, California
AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0102)
Orlando, Florida
University of Chicago Medical Center ( Site 0109)
Chicago, Illinois
University of Iowa ( Site 0110)
Iowa City, Iowa
Icahn School of Medicine at Mount Sinai ( Site 0101)
New York, New York
Duke Cancer Institute ( Site 0107)
Durham, North Carolina
Cleveland Clinic Main ( Site 0100)
Cleveland, Ohio
Fox Chase Cancer Center ( Site 0106)
Philadelphia, Pennsylvania
UT Southwestern Medical Center ( Site 0103)
Dallas, Texas
Houston Methodist Hospital-Department of Urology ( Site 0111)
Houston, Texas
Macquarie University-MQ Health Clinical Trials Unit ( Site 1803)
Macquarie University, New South Wales, Australia
Westmead Hospital ( Site 1802)
Westmead, New South Wales, Australia
Mater Misericordiae Limited ( Site 1808)
South Brisbane, Queensland, Australia
One Clinical Research ( Site 1807)
Nedlands, Western Australia, Australia
BC Cancer Vancouver ( Site 0004)
Vancouver, British Columbia, Canada
Princess Margaret Cancer Centre ( Site 0003)
Toronto, Ontario, Canada
Centre Hospitalier de l'Université de Montréal ( Site 0005)
Montreal, Quebec, Canada
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0001)
Québec, Quebec, Canada
Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0002)
Sherbrooke, Quebec, Canada
CIDO SpA ( Site 1509)
Temuco, Araucania, Chile
Bradfordhill-Clinical Area ( Site 1501)
Recoleta, Santiago, Region M. de Santiago, Chile
FALP ( Site 1500)
Santiago, Region M. de Santiago, Chile
Pontificia Universidad Catolica de Chile ( Site 1503)
Santiago, Region M. de Santiago, Chile
ONCOCENTRO APYS-ACEREY ( Site 1506)
Viña del Mar, Valparaiso, Chile
Clínica Universitaria Colombia ( Site 1600)
Bogotá, Bogota D.C., Colombia
Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 1605)
Valledupar, Cesar Department, Colombia
Instituto Nacional De Cancerologia-Oncología Clínica ( Site 1606)
Bogota, Cundinamarca, Colombia
Fundacion Valle del Lili- CIC-Oncology CIC ( Site 1608)
Cali, Valle del Cauca Department, Colombia
Hôpital Saint-Louis ( Site 0304)
Paris, France
Oncopole Claudius Regaud ( Site 0302)
Toulouse, Haute-Garonne, France
Gustave Roussy ( Site 0303)
Villejuif, Île-de-France Region, France
Institut de Cancérologie de l'Ouest ( Site 0300)
Angers, Maine-et-Loire, France
Hopital Claude Huriez - CHU de Lille ( Site 0301)
Lille, Nord, France
Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 0400)
Berlin, Germany
klinikum rechts der isar der technischen universität münchen-Urologische Klinik und Poliklinik ( Site 0401)
Munich, Bavaria, Germany
Caritas-Krankenhaus St. Josef-Klinik fuer Urologie ( Site 0404)
Regensburg, Bavaria, Germany
Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Urologie ( Site 0405)
Dresden, Saxony, Germany
Universitätsklinikum Halle-Universitätsklinik und Poliklinik für Urologie ( Site 0402)
Halle, Saxony-Anhalt, Germany
Ospedale San Raffaele-Oncologia Medica ( Site 0501)
Milan, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 0504)
Rome, Lazio, Italy
Showing 40 of 74 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.